Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a randomized phase 3 trial Conference

Mehta, MP, Carrie, C, Mahe, MA et al. (2006). Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a randomized phase 3 trial . INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S23-S23. 10.1016/j.ijrobp.2006.07.068

Industry Collaboration International Collaboration

cited authors

  • Mehta, MP; Carrie, C; Mahe, MA; Roa, W; Nieder, C; Ung, Y; Eble, M; Phan, SC; Smith, JA; Renschler, MF

sustainable development goals

authors

date/time interval

  • November 5, 2006 -

publication date

  • January 1, 2006

webpage

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Radiology, Nuclear Medicine & Medical Imaging
  • Science & Technology

Location

  • Philadelphia, PA

Digital Object Identifier (DOI)

Conference

  • 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)

publisher

  • ELSEVIER SCIENCE INC

start page

  • S23

end page

  • S23

volume

  • 66

issue

  • 3